Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times
Identifieur interne : 000887 ( PascalFrancis/Checkpoint ); précédent : 000886; suivant : 000888Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times
Auteurs : YING JIAO ZHAO [Singapour] ; HWEE LIN WEE [Singapour] ; Yiong-Huak Chan [Singapour] ; SOO HOON SEAH [Singapour] ; WING LOK AU [Singapour] ; PUAY NGOH LAU [Singapour] ; Emmanuel Camara Pica [Singapour] ; SHU CHUEN LI [Australie] ; NAN LUO [Singapour] ; Louis C. S. Tan [Singapour]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:10-0233091Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</title><author><name sortKey="Ying Jiao Zhao" sort="Ying Jiao Zhao" uniqKey="Ying Jiao Zhao" last="Ying Jiao Zhao">YING JIAO ZHAO</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Hwee Lin Wee" sort="Hwee Lin Wee" uniqKey="Hwee Lin Wee" last="Hwee Lin Wee">HWEE LIN WEE</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Soo Hoon Seah" sort="Soo Hoon Seah" uniqKey="Soo Hoon Seah" last="Soo Hoon Seah">SOO HOON SEAH</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Wing Lok Au" sort="Wing Lok Au" uniqKey="Wing Lok Au" last="Wing Lok Au">WING LOK AU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Puay Ngoh Lau" sort="Puay Ngoh Lau" uniqKey="Puay Ngoh Lau" last="Puay Ngoh Lau">PUAY NGOH LAU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Camara Pica, Emmanuel" sort="Camara Pica, Emmanuel" uniqKey="Camara Pica E" first="Emmanuel" last="Camara Pica">Emmanuel Camara Pica</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Shu Chuen Li" sort="Shu Chuen Li" uniqKey="Shu Chuen Li" last="Shu Chuen Li">SHU CHUEN LI</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1><s3>AUS</s3><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</wicri:noRegion></affiliation></author><author><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0233091</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0233091 INIST</idno><idno type="RBID">Pascal:10-0233091</idno><idno type="wicri:Area/PascalFrancis/Corpus">000B66</idno><idno type="wicri:Area/PascalFrancis/Curation">002153</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000887</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</title><author><name sortKey="Ying Jiao Zhao" sort="Ying Jiao Zhao" uniqKey="Ying Jiao Zhao" last="Ying Jiao Zhao">YING JIAO ZHAO</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Hwee Lin Wee" sort="Hwee Lin Wee" uniqKey="Hwee Lin Wee" last="Hwee Lin Wee">HWEE LIN WEE</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Soo Hoon Seah" sort="Soo Hoon Seah" uniqKey="Soo Hoon Seah" last="Soo Hoon Seah">SOO HOON SEAH</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Wing Lok Au" sort="Wing Lok Au" uniqKey="Wing Lok Au" last="Wing Lok Au">WING LOK AU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Puay Ngoh Lau" sort="Puay Ngoh Lau" uniqKey="Puay Ngoh Lau" last="Puay Ngoh Lau">PUAY NGOH LAU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Camara Pica, Emmanuel" sort="Camara Pica, Emmanuel" uniqKey="Camara Pica E" first="Emmanuel" last="Camara Pica">Emmanuel Camara Pica</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Shu Chuen Li" sort="Shu Chuen Li" uniqKey="Shu Chuen Li" last="Shu Chuen Li">SHU CHUEN LI</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1><s3>AUS</s3><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</wicri:noRegion></affiliation></author><author><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation><affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term><term>Parkinson disease</term><term>Transition</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Transition</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>25</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</s1></fA08><fA11 i1="01" i2="1"><s1>YING JIAO ZHAO</s1></fA11><fA11 i1="02" i2="1"><s1>HWEE LIN WEE</s1></fA11><fA11 i1="03" i2="1"><s1>CHAN (Yiong-Huak)</s1></fA11><fA11 i1="04" i2="1"><s1>SOO HOON SEAH</s1></fA11><fA11 i1="05" i2="1"><s1>WING LOK AU</s1></fA11><fA11 i1="06" i2="1"><s1>PUAY NGOH LAU</s1></fA11><fA11 i1="07" i2="1"><s1>CAMARA PICA (Emmanuel)</s1></fA11><fA11 i1="08" i2="1"><s1>SHU CHUEN LI</s1></fA11><fA11 i1="09" i2="1"><s1>NAN LUO</s1></fA11><fA11 i1="10" i2="1"><s1>TAN (Louis C. S.)</s1></fA11><fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1><s3>AUS</s3><sZ>8 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></fA14><fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1><s3>SGP</s3><sZ>9 aut.</sZ></fA14><fA20><s1>710-716</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000181078480070</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>28 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0233091</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Transition</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Transition</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Transición</s0><s5>09</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>158</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Singapour</li></country><orgName><li>Université nationale de Singapour</li></orgName></list><tree><country name="Singapour"><noRegion><name sortKey="Ying Jiao Zhao" sort="Ying Jiao Zhao" uniqKey="Ying Jiao Zhao" last="Ying Jiao Zhao">YING JIAO ZHAO</name></noRegion><name sortKey="Camara Pica, Emmanuel" sort="Camara Pica, Emmanuel" uniqKey="Camara Pica E" first="Emmanuel" last="Camara Pica">Emmanuel Camara Pica</name><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><name sortKey="Hwee Lin Wee" sort="Hwee Lin Wee" uniqKey="Hwee Lin Wee" last="Hwee Lin Wee">HWEE LIN WEE</name><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name><name sortKey="Puay Ngoh Lau" sort="Puay Ngoh Lau" uniqKey="Puay Ngoh Lau" last="Puay Ngoh Lau">PUAY NGOH LAU</name><name sortKey="Soo Hoon Seah" sort="Soo Hoon Seah" uniqKey="Soo Hoon Seah" last="Soo Hoon Seah">SOO HOON SEAH</name><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><name sortKey="Wing Lok Au" sort="Wing Lok Au" uniqKey="Wing Lok Au" last="Wing Lok Au">WING LOK AU</name></country><country name="Australie"><noRegion><name sortKey="Shu Chuen Li" sort="Shu Chuen Li" uniqKey="Shu Chuen Li" last="Shu Chuen Li">SHU CHUEN LI</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000887 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000887 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:10-0233091
|texte= Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times
}}
| This area was generated with Dilib version V0.6.23. |  |